ArticleJournal of clinical laboratory analysis2018
M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection.
Article in Journal of clinical laboratory analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa.Journal of global health · 2022Pooled it
- Role of mac-2 binding protein glycosylation isomer in predicting fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Article
- Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B.World journal of hepatology · 2025Article
- Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B.Digestive diseases and sciences · 2023Article
- Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.Annals of laboratory medicine · 2021Review
- Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.Journal of gastroenterology · 2018Review
- M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection.Journal of clinical laboratory analysis · 2018Article
- Real-time observation of pathophysiological processes during murine experimentalTropical medicine and health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundM2BPGi is a novel serum glycobiomarker of liver fibrosis. In this study, we aimed to evaluate the efficacy of M2BPGi for predicting liver fibrosis and disease progression in Chinese hepatitis B virus (HBV) infected patients.
methodsWe enrolled 228 HBV infected patients with different status of liver fibrosis diagnosed using FibroScan. We analyzed the diagnostic accuracy of M2BPGi, and compared it with AST-to-platelet ratio (APRI), FIB-4 index, AST to ALT ratio (AAR), and RDW to platelet ratio (RPR). We performed receiver operating characteristics curve (ROC) to evaluate the diagnostic performance of M2BPGi for significant fibrosis and cirrhosis.
resultsMedian M2BPGi values in each fibrosis stage were: 0.88 cut-off index (COI) in F0-1, 1.165 in F2-3, and 1.92 in F4 (P<.01), respectively. For F≥2, the sensitivity, specificity, accuracy of M2BPGi were 72.28%, 73.23%, 66.67%, while 55.07%, 93.71%, 82.02% for F≥4. For predicting significant fibrosis (≥F2), M2BPGi showed comparable performance to FIB4 index (P<.01), APRI (P<.01) and RPR (P<.01) with area under the ROC curve (AUC) of 0.788. M2BPGi was superior to other surrogate markers for diagnosing cirrhosis (F4) with the highest AUC of 0.811 (P<.01).
conclusionsM2BPGi levels increased with the progression of liver fibrosis in HBV infected patients. M2BPGi can be served as a potential glycobiomarker to assess the stage of liver fibrosis, especially for the diagnosis of cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.